Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 1
1998 1
1999 1
2000 2
2002 1
2003 1
2006 1
2007 1
2008 4
2009 4
2010 2
2011 2
2012 3
2013 3
2014 5
2015 1
2016 1
2017 1
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Prevalence of tremor and Parkinson's disease.
Khatter AS, Kurth MC, Brewer MA, Crinnian CT, Drazkowski JF, Flitman SS, Imke S, Spector SA, Wood KL, Lieberman AN. Khatter AS, et al. Among authors: flitman ss. Parkinsonism Relat Disord. 1996 Oct;2(4):205-8. doi: 10.1016/s1353-8020(96)00027-2. Parkinsonism Relat Disord. 1996. PMID: 18591041
Occipital nerve blocks: when and what to inject?
Tobin J, Flitman S. Tobin J, et al. Among authors: flitman s. Headache. 2009 Nov-Dec;49(10):1521-33. doi: 10.1111/j.1526-4610.2009.01493.x. Epub 2009 Aug 6. Headache. 2009. PMID: 19674126 Review.
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O; BouNDless Study Group. Espay AJ, et al. Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15. Lancet Neurol. 2024. PMID: 38499015 Clinical Trial.
Brain activation during script event processing.
Partiot A, Grafman J, Sadato N, Flitman S, Wild K. Partiot A, et al. Among authors: flitman s. Neuroreport. 1996 Feb 29;7(3):761-6. doi: 10.1097/00001756-199602290-00020. Neuroreport. 1996. PMID: 8733740 Clinical Trial.
Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.
French JA, Cole AJ, Faught E, Theodore WH, Vezzani A, Liow K, Halford JJ, Armstrong R, Szaflarski JP, Hubbard S, Patel J, Chen K, Feng W, Rizzo M, Elkins J, Knafler G, Parkerson KA; OPUS Study Group. French JA, et al. Neurology. 2021 Nov 2;97(18):e1757-e1767. doi: 10.1212/WNL.0000000000012766. Epub 2021 Sep 14. Neurology. 2021. PMID: 34521687 Free PMC article. Clinical Trial.
36 results